Skip to main content
. 2013 Aug 1;36(8):1129–1138. doi: 10.5665/sleep.2870

Figure 4.

Figure 4

AAV-orexin improved maintenance of wakefulness. Time-weighted frequency histograms of wake bouts during the dark period show that in WT mice treated with AAV-mCherry or AAV-orexin, 33-47% of wakefulness occurred in bouts longer than 2,550 s (42.5 min). In contrast, most wakefulness in Atx mice treated with AAV-mCherry occurred in bouts lasting only 320-630 s (5.3-10.5 min) with almost no wakefulness occurring in very long bouts. In Atx mice treated with AAV-orexin, 20% of all wake occurred in very long wake bouts. *P < 0.01 compared to WT AAV-mCherry mice. #P < 0.01 between Atx AAV-mCherry and Atx AAV-orexin mice. AAV, adeno-associated viral vector; Atx, transgenic (ataxin); WT, wild type.